Seoul, South Korea

Kang-Yo Lee

This inventor holds 1 USPTO granted patent. Top assignee: Yuhan Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kang-Yo Lee. Retrieved from https://idiyas.com/inventor/kang-yo-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kang-Yo Lee: Inventor in Pharmaceutical Research

Introduction

Kang-Yo Lee is an inventor based in Seoul, South Korea, and works at Yuhan Corporation. His patent work concerns pharmaceutical compounds and potential treatments for diseases associated with the lysyl oxidase family.

Latest Patents

Lee is associated with 1 patent: “Bicyclic fused ring derivative or salt thereof and pharmaceutical composition comprising same.” The invention describes bicyclic fused-ring derivatives, including benzo[d]imidazole, benzo[d][1,2,3]triazole, and 8-oxo-8,9-dihydro-7H-purine derivatives, as well as pharmaceutically acceptable salts, preparation methods, pharmaceutical compositions, and uses.

The patent describes inhibitory activity against the lysyl oxidase family and potential applications in preventing or treating related diseases, including idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, chronic kidney disease, and liver cirrhosis.

Career Highlights

Lee’s listed invention reflects work at the intersection of medicinal chemistry and therapeutic development. Its proposed applications focus on conditions associated with lysyl oxidase family activity.

Collaborations

Lee’s listed coworkers include Eun-kyung Kim and Cheol-Hee Lim. The patent is associated with Yuhan Corporation.

Conclusion

Kang-Yo Lee’s patent work at Yuhan Corporation centers on a bicyclic fused-ring pharmaceutical approach with potential applications across several serious diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…